255 studies found for:    akt cancer
Show Display Options
Rank Status Study
1 Active, not recruiting A Phase II Study of Akt Inhibitor MK2206 in the Treatment of Recurrent Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer
Conditions: Ovarian Sarcoma;   Recurrent Fallopian Tube Cancer;   Recurrent Ovarian Epithelial Cancer;   Recurrent Primary Peritoneal Cavity Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
2 Recruiting AKT Inhibitor in Oestrogen Positive Breast Cancer
Condition: Invasive Breast Cancer
Intervention: Drug: AZD5363
3 Recruiting Dinaciclib and Akt Inhibitor MK2206 in Treating Patients With Pancreatic Cancer That Cannot Be Removed By Surgery
Conditions: Acinar Cell Adenocarcinoma of the Pancreas;   Duct Cell Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage III Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: dinaciclib;   Drug: Akt inhibitor MK2206;   Other: pharmacological study;   Other: laboratory biomarker analysis
4 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Advanced Breast Cancer
Conditions: Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
5 Active, not recruiting Akt Inhibitor MK2206 in Combination With Lapatinib Ditosylate in Patients With Advanced or Metastatic Solid Tumors or Breast Cancer
Conditions: HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer;   Stage IV Breast Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: pharmacological study;   Other: laboratory biomarker analysis
6 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Advanced Gastric or Gastroesophageal Junction Cancer
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   Adenocarcinoma of the Stomach;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer
Intervention: Drug: Akt inhibitor MK2206
7 Active, not recruiting Lapatinib Ditosylate and Akt Inhibitor MK2206 in Treating Women With Metastatic Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   Estrogen Receptor-positive Breast Cancer;   HER2-positive Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Progesterone Receptor-positive Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Other: pharmacological study
8 Recruiting Akt Inhibitor MK2206 and Hydroxychloroquine in Treating Patients With Advanced Solid Tumors, Melanoma, Prostate or Kidney Cancer
Conditions: Hormone-resistant Prostate Cancer;   Recurrent Melanoma;   Recurrent Prostate Cancer;   Recurrent Renal Cell Cancer;   Stage IIIA Melanoma;   Stage IIIB Melanoma;   Stage IIIC Melanoma;   Stage IV Melanoma;   Stage IV Prostate Cancer;   Stage IV Renal Cell Cancer;   Unspecified Adult Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor MK2206;   Drug: hydroxychloroquine;   Other: pharmacological study;   Other: laboratory biomarker analysis
9 Suspended GSK2141795 and Dabrafenib in Treating Patients With Stage IIIC-IV Cancer
Conditions: Recurrent Colon Cancer;   Recurrent Melanoma;   Recurrent Ovarian Epithelial Cancer;   Recurrent Ovarian Germ Cell Tumor;   Stage IIIC Colon Cancer;   Stage IIIC Melanoma;   Stage IIIC Ovarian Epithelial Cancer;   Stage IIIC Ovarian Germ Cell Tumor;   Stage IV Melanoma;   Unspecified Adult Solid Tumor, Protocol Specific;   Unspecified Childhood Solid Tumor, Protocol Specific
Interventions: Drug: Akt inhibitor GSK2141795;   Drug: dabrafenib;   Other: laboratory biomarker analysis;   Other: pharmacological study
10 Recruiting Bicalutamide With or Without Akt Inhibitor MK2206 in Treating Patients With Previously Treated Prostate Cancer
Conditions: Recurrent Prostate Cancer;   Stage I Prostate Cancer;   Stage IIA Prostate Cancer;   Stage IIB Prostate Cancer;   Stage III Prostate Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: bicalutamide;   Other: clinical observation
11 Completed A Study of the Safety and Activity of the MEK Inhibitor Given Together With the AKT Inhibitor to Patients With Multiple Myeloma or Solid Tumor Cancers
Condition: Cancer
Interventions: Drug: GSK1120212;   Drug: GSK2110183
12 Terminated Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gastroesophageal Junction;   HER2-positive Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Recurrent Esophageal Cancer;   Recurrent Gastric Cancer;   Stage IIIC Breast Cancer;   Stage IIIC Esophageal Cancer;   Stage IIIC Gastric Cancer;   Stage IV Breast Cancer;   Stage IV Esophageal Cancer;   Stage IV Gastric Cancer
Interventions: Drug: Akt inhibitor MK2206;   Biological: trastuzumab;   Drug: lapatinib ditosylate;   Other: laboratory biomarker analysis
13 Recruiting Trametinib and Akt Inhibitor GSK2141795 in Treating Patients With Metastatic Triple-Negative Breast Cancer
Conditions: Estrogen Receptor-negative Breast Cancer;   HER2-negative Breast Cancer;   Male Breast Cancer;   Progesterone Receptor-negative Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer;   Triple-negative Breast Cancer
Interventions: Drug: trametinib;   Drug: Akt inhibitor GSK2141795;   Other: laboratory biomarker analysis
14 Recruiting Selumetinib and Akt Inhibitor MK2206 or mFOLFOX Therapy Comprising Oxaliplatin and Fluorouracil in Treating Patients With Metastatic Pancreatic Cancer Previously Treated With Chemotherapy
Conditions: Adenocarcinoma of the Pancreas;   Recurrent Pancreatic Cancer;   Stage IV Pancreatic Cancer
Interventions: Drug: Akt inhibitor MK2206;   Drug: selumetinib;   Drug: oxaliplatin;   Drug: fluorouracil
15 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Progressive, Recurrent, or Metastatic Adenoid Cyst Carcinoma
Conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity;   Recurrent Salivary Gland Cancer;   Salivary Gland Adenoid Cystic Carcinoma;   Stage IVA Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVA Salivary Gland Cancer;   Stage IVB Adenoid Cystic Carcinoma of the Oral Cavity;   Stage IVB Salivary Gland Cancer;   Stage IVC Adenoid Cystic Carcinoma of the Oral Cavity
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
16 Recruiting Akt Inhibitor MK2206 in Treating Patients With Previously Treated Colon or Rectal Cancer That is Metastatic or Cannot Removed by Surgery
Conditions: Mucinous Adenocarcinoma of the Colon;   Mucinous Adenocarcinoma of the Rectum;   Recurrent Colon Cancer;   Recurrent Rectal Cancer;   Signet Ring Adenocarcinoma of the Colon;   Signet Ring Adenocarcinoma of the Rectum;   Stage IIIA Colon Cancer;   Stage IIIA Rectal Cancer;   Stage IIIB Colon Cancer;   Stage IIIB Rectal Cancer;   Stage IIIC Colon Cancer;   Stage IIIC Rectal Cancer;   Stage IVA Colon Cancer;   Stage IVA Rectal Cancer;   Stage IVB Colon Cancer;   Stage IVB Rectal Cancer
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacological study
17 Completed MK2206 in Treating Younger Patients With Recurrent or Refractory Solid Tumors or Leukemia
Conditions: Acute Undifferentiated Leukemia;   Angioimmunoblastic T-cell Lymphoma;   Childhood Burkitt Lymphoma;   Childhood Chronic Myelogenous Leukemia;   Childhood Diffuse Large Cell Lymphoma;   Childhood Grade III Lymphomatoid Granulomatosis;   Childhood Immunoblastic Large Cell Lymphoma;   Childhood Nasal Type Extranodal NK/T-cell Lymphoma;   Cutaneous B-cell Non-Hodgkin Lymphoma;   Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue;   Intraocular Lymphoma;   Juvenile Myelomonocytic Leukemia;   Mast Cell Leukemia;   Nodal Marginal Zone B-cell Lymphoma;   Post-transplant Lymphoproliferative Disorder;   Primary Central Nervous System Hodgkin Lymphoma;   Primary Central Nervous System Non-Hodgkin Lymphoma;   Progressive Hairy Cell Leukemia, Initial Treatment;   Prolymphocytic Leukemia;   Recurrent Childhood Acute Lymphoblastic Leukemia;   Recurrent Childhood Acute Myeloid Leukemia;   Recurrent Childhood Anaplastic Large Cell Lymphoma;   Recurrent Childhood Grade III Lymphomatoid Granulomatosis;   Recurrent Childhood Large Cell Lymphoma;   Recurrent Childhood Lymphoblastic Lymphoma;   Recurrent Childhood Small Noncleaved Cell Lymphoma;   Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma;   Recurrent Grade 1 Follicular Lymphoma;   Recurrent Grade 2 Follicular Lymphoma;   Recurrent Grade 3 Follicular Lymphoma;   Recurrent Mantle Cell Lymphoma;   Recurrent Marginal Zone Lymphoma;   Recurrent Mycosis Fungoides/Sezary Syndrome;   Recurrent Small Lymphocytic Lymphoma;   Recurrent/Refractory Childhood Hodgkin Lymphoma;   Refractory Chronic Lymphocytic Leukemia;   Refractory Hairy Cell Leukemia;   Relapsing Chronic Myelogenous Leukemia;   Secondary Acute Myeloid Leukemia;   Small Intestine Lymphoma;   Splenic Marginal Zone Lymphoma;   T-cell Large Granular Lymphocyte Leukemia;   Unspecified Childhood Solid Tumor, Protocol Specific;   Waldenström Macroglobulinemia
Interventions: Drug: Akt inhibitor MK2206;   Other: diagnostic laboratory biomarker analysis;   Other: pharmacological study
18 Terminated Selumetinib and Akt Inhibitor MK-2206 in Treating Patients With Refractory or Advanced Gallbladder or Bile Duct Cancer That Cannot Be Removed By Surgery
Conditions: Adenocarcinoma of the Gallbladder;   Adenocarcinoma With Squamous Metaplasia of the Gallbladder;   Adult Primary Cholangiocellular Carcinoma;   Advanced Adult Primary Liver Cancer;   Cholangiocarcinoma of the Extrahepatic Bile Duct;   Localized Unresectable Adult Primary Liver Cancer;   Metastatic Extrahepatic Bile Duct Cancer;   Recurrent Adult Primary Liver Cancer;   Recurrent Extrahepatic Bile Duct Cancer;   Stage II Gallbladder Cancer;   Stage IIIA Gallbladder Cancer;   Stage IIIB Gallbladder Cancer;   Stage IVA Gallbladder Cancer;   Stage IVB Gallbladder Cancer;   Unresectable Extrahepatic Bile Duct Cancer
Interventions: Drug: selumetinib;   Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis;   Other: pharmacogenomic studies;   Procedure: quality-of-life assessment
19 Active, not recruiting Akt Inhibitor MK2206 in Treating Patients With Recurrent or Advanced Endometrial Cancer
Conditions: Endometrial Adenocarcinoma;   Endometrial Adenosquamous Cell Carcinoma;   Endometrial Clear Cell Carcinoma;   Endometrial Papillary Serous Carcinoma;   Recurrent Endometrial Carcinoma
Interventions: Drug: Akt inhibitor MK2206;   Other: laboratory biomarker analysis
20 Recruiting Continuation Study of the Oral AKT Inhibitor GSK2110183
Condition: Cancer
Intervention: Drug: GSK2110183

Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results
Indicates status has not been verified in more than two years